Californian medical company Second Sight has been granted conditional approval by the US Food and Drug Administration to a small clinical trial of its new device , the Orion , which could restore some vision to patients with retinitis A . The Orion takes much of its technology from Second Sight 's previous device , the Argus II , but also includes devices implanted directly into the brain to bypass the brain and the optic nerve . The company said people who are blind due to other illnesses could " hypothetically " use the Orion .
Californian medical company Second Sight has been granted conditional approval by the US Food and Drug Administration to conduct small clinical trial of its new device, the Orion, which could restore some vision to patients with retinitis pigmentosa. The Orion borrows much of its technology from Second Sight's previous model, the Argus II, but also includes electrodes implanted directly into the brain to bypass the eye and the optic nerve. The company said people who are blind due to other illnesses could "hypothetically" use the Orion.